128 related articles for article (PubMed ID: 25847480)
1. A phase I study of resminostat in Japanese patients with advanced solid tumors.
Kitazono S; Fujiwara Y; Nakamichi S; Mizugaki H; Nokihara H; Yamamoto N; Yamada Y; Inukai E; Nakamura O; Tamura T
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1155-61. PubMed ID: 25847480
[TBL] [Abstract][Full Text] [Related]
2. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
8. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M; Ohno I; Ueno H; Mitsunaga S; Hashimoto Y; Okusaka T; Kondo S; Sasaki M; Sakamoto Y; Takahashi H; Hara R; Kobayashi S; Nakamura O; Morizane C
Invest New Drugs; 2019 Feb; 37(1):109-117. PubMed ID: 29995287
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Yeo W; Chung HC; Chan SL; Wang LZ; Lim R; Picus J; Boyer M; Mo FK; Koh J; Rha SY; Hui EP; Jeung HC; Roh JK; Yu SC; To KF; Tao Q; Ma BB; Chan AW; Tong JH; Erlichman C; Chan AT; Goh BC
J Clin Oncol; 2012 Sep; 30(27):3361-7. PubMed ID: 22915658
[TBL] [Abstract][Full Text] [Related]
12. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
13. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
[TBL] [Abstract][Full Text] [Related]
18. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC; Wang J; Khountham S; Monk P; Shapiro CL; Piekarz R; Hofmeister CC; Welling DB; Mortazavi A
Cancer Chemother Pharmacol; 2021 May; 87(5):599-611. PubMed ID: 33492438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
